DOCSLIB.ORG

Congenital Hypothyroidism: Insights Into Pathogenesis and Treatment Christine E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Cherella and Wassner International Journal of Pediatric Endocrinology (2017) 2017:11 DOI 10.1186/s13633-017-0051-0 REVIEW Open Access Congenital hypothyroidism: insights into pathogenesis and treatment Christine E. Cherella and Ari J. Wassner* Abstract Congenital hypothyroidism occurs in approximately 1 in 2000 newborns and can have devastating neurodevelopmental consequences if not detected and treated promptly. While newborn screening has virtually eradicated intellectual disability due to severe congenital hypothyroidism in the developed world, more stringent screening strategies have resulted in increased detection of mild congenital hypothyroidism. Recent studies provide conflicting evidence about the potential neurodevelopmental risks posed by mild congenital hypothyroidism, highlighting the need for additional research to further define what risks these patients face and whether they are likely to benefit from treatment. Moreover, while the apparent incidence of congenital hypothyroidism has increased in recent decades, the underlying cause remains obscure in most cases. However, ongoing research into genetic causes of congenital hypothyroidism continues to shed new light on the development and physiology of the hypothalamic-pituitary-thyroid axis. The identification of IGSF1 as a cause of central congenital hypothyroidism has uncovered potential new regulatory pathways in both pituitary thyrotropes and gonadotropes, while mounting evidence suggests that a significant proportion of primary congenital hypothyroidism may be caused by combinations of rare genetic variants in multiple genes involved in thyroid development and function. Much remains to be learned about the origins of this common disorder and about the optimal management of less severely-affected infants. Keywords: Congenital hypothyroidism, Genetics, Central hypothyroidism, Mild hypothyroidism Background detection and treatment are indisputable, uncertainty Thyroid hormone is essential for normal growth and remains about mild disease in terms of the neurodeve- neurologic development, particularly in the first few lopmental risk it poses and whether these risks are years of life, and hypothyroidism during this period is a mitigated by treatment [7]. Moreover, despite the leading cause of preventable intellectual disability world- prevalence of congenital hypothyroidism and our suc- wide. The implementation of universal newborn screening cess in treating it, what causes most cases remains a beginning in the 1970’s has been an enormous public mystery. This review discusses important recent develop- health success, virtually eradicating significant intellectual ments in congenital hypothyroidism, focusing on our disability due to severe congenital hypothyroidism in the evolving understanding of its genetics, pathophysiology, developed world. Following this early success, newborn and outcomes. screening programs have implemented increasingly stringent screening strategies over the past few decades. The resulting detection of milder cases of congenital Primary congenital hypothyroidism hypothyroidism is the primary reason for the dramatic Most congenital hypothyroidism is caused by defects in increase in the apparent incidence of congenital the thyroid gland itself (primary hypothyroidism). Causes hypothyroidism from 1:4000 to 1:2000 newborns over of primary congenital hypothyroidism can be broadly clas- the last 20–30 years [1–6].However,unlikeseverecon- sified as failure of the thyroid gland to develop normally genital hypothyroidism, for which the benefits of early (dysgenesis) or failure of a structurally normal thyroid gland to produce normal quantities of thyroid hormone (dyshormonogenesis). Thyroid dysgenesis—which encom- * Correspondence: [email protected] Division of Endocrinology, Boston Children’s Hospital, Harvard Medical passes the spectrum of thyroid agenesis, hypoplasia, and School, 300 Longwood Avenue, Boston, MA 02115, USA ectopy—is the most common cause of congenital © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Cherella and Wassner International Journal of Pediatric Endocrinology (2017) 2017:11 Page 2 of 8 hypothyroidism, and its incidence (about 1:4000 infants) preciseroleofNKX2–5 in thyroid dysgenesis remains has not changed significantly over the last several decades to be clarified [8]. [3,5,6].Theunderlyingcauseofthyroiddysgenesis, Mutations in GLIS3 underlie a complex syndrome of however, remains obscure in the vast majority of cases. congenital hypothyroidism, neonatal diabetes mellitus, Thyroid dysgenesis usually occurs sporadically, with only and variable other abnormalities including congenital 2–5% of cases being attributable to identifiable genetic glaucoma, developmental delay, hepatic fibrosis, and mutations (Fig. 1). Nevertheless, the known genetic causes polycystic kidneys [12, 13]. GLIS3 is highly expressed in of thyroid dysgenesis provide an important window into the thyroid, and congenital hypothyroidism in patients basic thyroid ontogeny. The thyroid-stimulating hormone with GLIS3 mutations may be associated with either thy- receptor (TSHR) and the transcription factors PAX8, roid dysgenesis or a eutopic but histologically abnormal NKX2–1,andFOXE1 are all expressed in the developing thyroid gland [13]. GLIS3 may act as a transcriptional thyroid, and disruption of any of these genes can lead to activator or repressor, but its precise role in thyroid de- failure of normal thyroid gland formation [8]. These velopment and function remains to be determined. Some transcription factors also play important roles in other de- patients with GLIS3 mutations require unusually high veloping tissues, and mutations in each may be associated doses of levothyroxine to normalize serum thyroid with additional syndromic features such as renal abnor- stimulating hormone (TSH) levels [13, 14], which could malities (PAX8), interstitial lung disease and chorea imply an additional effect of GLIS3 on central regulation (NKX2–1), or cleft palate, bifid epiglottis, choanal atresia, of the hypothalamic-pituitary-thyroid (HPT) axis. and spiky hair (FOXE1)(Table1). Recently, genetic variants in CDCA8 (also called Several other genes implicated in thyroid dysgenesis BOREALIN) were identified in a study of three consan- offer additional insights into the mechanisms of thyroid de- guineous families with thyroid dysgenesis [15]. This gene velopment. The transcription factor NKX2–5 is expressed is expressed in the thyroid and is known to play a key in the developing heart and thyroid, and NKX2–5 muta- role in the chromosomal passenger complex that tions are associated with congenital cardiac abnormalities. stabilizes the mitotic spindle during cell division. Deletion of NKX2–5 in mice causes thyroid agenesis, sug- Interestingly, however, the CDCA8 variants detected gesting that this transcription factor plays an important in these patients do not appear to affect mitosis but role in thyroid development, but to what degree this rather impair cell migration and adhesion in vitro. finding extends to humans is not clear. Heterozygous vari- Thus, the potential mechanistic role of CDCA8 in thy- ants in NKX2–5 are found in some individuals with thyroid roid dysgenesis is still unclear, and the range of thy- dysgenesis[9,10];however,thepathogenicityofthesevari- roid phenotypes observed in patients carrying CDCA8 ants is unclear since they do not consistently cosegregate variants is broad, ranging from thyroid agenesis or ectopy with thyroid disease in families [9] and some may not to euthyroid individuals with asymmetric thyroid lobes or impair protein function in vitro [11]. Therefore, the thyroid nodules. Hypothalamic/ Pituitary Development Hypothalamus TRH / TSH HESX1 signaling LHX3 TRH TRHR LHX4 TSHB SOX3 IGSF1 OTX2 Pituitary TBL1X PROP1 LEPR POU1F1 TSH Thyroid Thyroid Hormone Development Synthesis TSHR Thyroid TG PAX8 TPO NKX2-1 DUOX2 FOXE1 DUOXA2 NKX2-5 T4, T3 SLC5A5 JAG1 SLC26A4 GLIS3 IYD CDCA8 Fig. 1 Genes associated with congenital hypothyroidism. TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine Cherella and Wassner International Journal of Pediatric Endocrinology (2017) 2017:11 Page 3 of 8 Table 1 Clinical features of genetic syndromes associated with congenital hypothyroidism Primary congenital hypothyroidism Central congenital hypothyroidism PAX8 Renal abnormalities IGSF1 Macro-orchidism, delayed pubertal testosterone rise, PRL deficiency, transient GH deficiency NKX2–1 Interstitial lung disease, chorea TBL1X Hearing deficits FOXE1 Cleft palate, bifid epiglottis, choanal atresia, LEPR Severe early-onset obesity, delayed puberty spiky hair (Bamforth-Lazarus syndrome) NKX2–5 Congenital heart disease POU1F1 Combined pituitary hormone deficiency GLIS3 Neonatal diabetes mellitus, congenital glaucoma, PROP1 Combined pituitary hormone deficiency developmental delay, hepatic fibrosis, polycystic kidneys JAG1 Alagille syndrome (variable
Recommended publications
  • Novel Binding Partners of PBF in Thyroid Tumourigenesis

    Novel Binding Partners of PBF in Thyroid Tumourigenesis

    NOVEL BINDING PARTNERS OF PBF IN THYROID TUMOURIGENESIS By Neil Sharma A thesis presented to the College of Medical and Dental Sciences at the University of Birmingham for the Degree of Doctor of Philosophy Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine August 2013 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. SUMMARY Thyroid cancer is the most common endocrine cancer, with a rising incidence. The proto-oncogene PBF is over-expressed in thyroid tumours, and the degree of over-expression is directly linked to patient survival. PBF causes transformation in vitro and tumourigenesis in vivo, with PBF-transgenic mice developing large, macro-follicular goitres, effects partly mediated by the internalisation and repression of the membrane-bound transporters NIS and MCT8. NIS repression leads to a reduction in iodide uptake, which may negatively affect the efficacy of radioiodine treatment, and therefore prognosis. Work within this thesis describes the use of tandem mass spectrometry to produce a list of potential binding partners of PBF. This will aid further research into the pathophysiology of PBF, not just in relation to thyroid cancer but also other malignancies.
  • Natural Course of Congenital Hypothyroidism by Dual Oxidase 2 Mutations from the Neonatal Period Through Puberty

    Natural Course of Congenital Hypothyroidism by Dual Oxidase 2 Mutations from the Neonatal Period Through Puberty

    Y Maruo and others Clinical features of DUOX2 174:4 453–463 Clinical Study defects Natural course of congenital hypothyroidism by dual oxidase 2 mutations from the neonatal period through puberty Yoshihiro Maruo1, Keisuke Nagasaki, Katsuyuki Matsui, Yu Mimura, Asami Mori, Maki Fukami2 and Yoshihiro Takeuchi Correspondence should be addressed Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192, Japan, to Y Maruo 1Department of Pediatrics, Niigata University, Niigata, Japan and 2Department of Molecular Endocrinology, Email National Research Institute for Child Health and Development, Tokyo, Japan [email protected] Abstract Aim: We previously reported that biallelic mutations in dual oxidase 2 (DUOX2) cause transient hypothyroidism. Since then, many cases with DUOX2 mutations have been reported. However, the clinical features and prognosis of individuals with DUOX2 defects have not been clarified. Objective: We investigated the prognosis of patients with congenital hypothyroidism (CH) due to DUOX2 mutations. Patients: Twenty-five patients were identified by a neonatal screening program and included seven familial cases. Their serum TSH values ranged from 18.9 to 734.6 mU/l. Twenty-two of the patients had low serum free thyroxine (fT4) levels (0.17–1.1 ng/dl). Twenty-four of the patients were treated with L-thyroxine. Methods: We analyzed the DUOX2, thyroid peroxidase, NaC/IK symporter, and dual oxidase maturation factor 2 genes of these 25 patients by PCR-amplified direct sequencing. An additional 11 genes were analyzed in 11 of the 25 patients using next-generation sequencing. Results: All patients had biallelic DUOX2 mutations, and seven novel alleles were detected.
  • A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255ter) in IGSF1 Gene

    A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255ter) in IGSF1 Gene

    Türkkahraman D et al. A Novel Variant in IGSF1 Gene CASE REPORT DO I: 10.4274/jcrpe.galenos.2020.2020.0149 J Clin Res Pediatr Endocrinol 2021;13(3):353-357 A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255Ter) in IGSF1 Gene Doğa Türkkahraman1, Nimet Karataş Torun2, Nadide Cemre Randa3 1University of Health Sciences Turkey, Antalya Training and Research Hospital, Clinic of Pediatric Endocrinology, Antalya, Turkey 2University of Healty Sciences Turkey, Antalya Training and Research Hospital, Clinic of Pediatrics, Antalya, Turkey 3University of Healty Sciences Turkey, Antalya Training and Research Hospital, Clinic of Medical Genetics, Antalya, Turkey What is already known on this topic? Mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene that mainly regulates pituitary thyrotrope function lead to X-linked hypothyroidism characterized by congenital hypothyroidism of central origin and testicular enlargement. The clinical features associated with IGSF1 mutations are variable, but prolactin and/or growth hormone deficiency, and discordance between timing of testicular growth and rise of serum testosterone levels could be seen. What this study adds? Genetic analysis revealed a novel c.3763C>T variant in the IGSF1 gene. To our knowledge, this is the first reported case of IGSF1 deficiency from Turkey. Additionally, as in our case, early testicular enlargement but delayed testosterone rise should be evaluated in all boys with central hypothyroidism, as macro-orchidism is usually seen in adulthood. Abstract Loss-of-function mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene cause X-linked central hypothyroidism, and therefore its mutation affects mainly males. Central hypothyroidism in males is the hallmark of the disorder, however some patients additionally present with hypoprolactinemia, transient and partial growth hormone deficiency, early/normal timing of testicular enlargement but delayed testosterone rise in puberty, and adult macro-orchidism.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature

    MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature

    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
  • Effects of Chronic Stress on Prefrontal Cortex Transcriptome in Mice Displaying Different Genetic Backgrounds

    Effects of Chronic Stress on Prefrontal Cortex Transcriptome in Mice Displaying Different Genetic Backgrounds

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector J Mol Neurosci (2013) 50:33–57 DOI 10.1007/s12031-012-9850-1 Effects of Chronic Stress on Prefrontal Cortex Transcriptome in Mice Displaying Different Genetic Backgrounds Pawel Lisowski & Marek Wieczorek & Joanna Goscik & Grzegorz R. Juszczak & Adrian M. Stankiewicz & Lech Zwierzchowski & Artur H. Swiergiel Received: 14 May 2012 /Accepted: 25 June 2012 /Published online: 27 July 2012 # The Author(s) 2012. This article is published with open access at Springerlink.com Abstract There is increasing evidence that depression signaling pathway (Clic6, Drd1a,andPpp1r1b). LA derives from the impact of environmental pressure on transcriptome affected by CMS was associated with genetically susceptible individuals. We analyzed the genes involved in behavioral response to stimulus effects of chronic mild stress (CMS) on prefrontal cor- (Fcer1g, Rasd2, S100a8, S100a9, Crhr1, Grm5,and tex transcriptome of two strains of mice bred for high Prkcc), immune effector processes (Fcer1g, Mpo,and (HA)and low (LA) swim stress-induced analgesia that Igh-VJ558), diacylglycerol binding (Rasgrp1, Dgke, differ in basal transcriptomic profiles and depression- Dgkg,andPrkcc), and long-term depression (Crhr1, like behaviors. We found that CMS affected 96 and 92 Grm5,andPrkcc) and/or coding elements of dendrites genes in HA and LA mice, respectively. Among genes (Crmp1, Cntnap4,andPrkcc) and myelin proteins with the same expression pattern in both strains after (Gpm6a, Mal,andMog). The results indicate significant CMS, we observed robust upregulation of Ttr gene contribution of genetic background to differences in coding transthyretin involved in amyloidosis, seizures, stress response gene expression in the mouse prefrontal stroke-like episodes, or dementia.
  • DUOX1 Mediates Persistent Epithelial EGFR Activation, Mucous Cell Metaplasia, and Airway Remodeling During Allergic Asthma

    DUOX1 Mediates Persistent Epithelial EGFR Activation, Mucous Cell Metaplasia, and Airway Remodeling During Allergic Asthma

    DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma Aida Habibovic, … , Miklos Geiszt, Albert van der Vliet JCI Insight. 2016;1(18):e88811. https://doi.org/10.1172/jci.insight.88811. Research Article Inflammation Pulmonology Chronic inflammation with mucous metaplasia and airway remodeling are hallmarks of allergic asthma, and these outcomes have been associated with enhanced expression and activation of EGFR signaling. Here, we demonstrate enhanced expression of EGFR ligands such as amphiregulin as well as constitutive EGFR activation in cultured nasal epithelial cells from asthmatic subjects compared with nonasthmatic controls and in lung tissues of mice during house dust mite–induced (HDM-induced) allergic inflammation. EGFR activation was associated with cysteine oxidation within EGFR and the nonreceptor tyrosine kinase Src, and both amphiregulin production and oxidative EGFR activation were diminished by pharmacologic or genetic inhibition of the epithelial NADPH oxidase dual oxidase 1 (DUOX1). DUOX1 deficiency also attenuated several EGFR-dependent features of HDM-induced allergic airway inflammation, including neutrophilic inflammation, type 2 cytokine production (IL-33, IL-13), mucous metaplasia, subepithelial fibrosis, and central airway resistance. Moreover, targeted inhibition of airway DUOX1 in mice with previously established HDM-induced allergic inflammation, by intratracheal administration of DUOX1-targeted siRNA or pharmacological NADPH oxidase inhibitors, reversed most of these outcomes. Our findings indicate an important function for DUOX1 in allergic inflammation related to persistent EGFR activation and suggest that DUOX1 targeting may represent an attractive strategy in asthma management. Find the latest version: https://jci.me/88811/pdf RESEARCH ARTICLE DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma Aida Habibovic,1 Milena Hristova,1 David E.
  • Genomic Evidence of Reactive Oxygen Species Elevation in Papillary Thyroid Carcinoma with Hashimoto Thyroiditis

    Genomic Evidence of Reactive Oxygen Species Elevation in Papillary Thyroid Carcinoma with Hashimoto Thyroiditis

    Endocrine Journal 2015, 62 (10), 857-877 Original Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis Jin Wook Yi1), 2), Ji Yeon Park1), Ji-Youn Sung1), 3), Sang Hyuk Kwak1), 4), Jihan Yu1), 5), Ji Hyun Chang1), 6), Jo-Heon Kim1), 7), Sang Yun Ha1), 8), Eun Kyung Paik1), 9), Woo Seung Lee1), Su-Jin Kim2), Kyu Eun Lee2)* and Ju Han Kim1)* 1) Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea 2) Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea 3) Department of Pathology, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea 4) Kwak Clinic, Okcheon-gun, Chungbuk, Korea 5) Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, Uijeongbu, Korea 6) Department of Radiation Oncology, Seoul St. Mary’s Hospital, Seoul, Korea 7) Department of Pathology, Chonnam National University Hospital, Kwang-Ju, Korea 8) Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 9) Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea Abstract. Elevated levels of reactive oxygen species (ROS) have been proposed as a risk factor for the development of papillary thyroid carcinoma (PTC) in patients with Hashimoto thyroiditis (HT). However, it has yet to be proven that the total levels of ROS are sufficiently increased to contribute to carcinogenesis. We hypothesized that if the ROS levels were increased in HT, ROS-related genes would also be differently expressed in PTC with HT. To find differentially expressed genes (DEGs) we analyzed data from the Cancer Genomic Atlas, gene expression data from RNA sequencing: 33 from normal thyroid tissue, 232 from PTC without HT, and 60 from PTC with HT.
  • Recent Developments in the Role of Reactive Oxygen Species in Allergic Asthma

    Recent Developments in the Role of Reactive Oxygen Species in Allergic Asthma

    43 Review Article Recent developments in the role of reactive oxygen species in allergic asthma Jingjing Qu1,2*, Yuanyuan Li1*, Wen Zhong1, Peisong Gao2, Chengping Hu1 1Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; 2Division of Allergy and Clinical Immunology, Johns Hopkins School of Medicine, Baltimore, MD, USA Contributions: (I) Conception and design: J Qu, Y Li, P Gao, C Hu; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: W Zhong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. *These authors contributed equally to this work. Correspondence to: Chengping Hu. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China. Email: [email protected]; Peisong Gao, MD, PhD. The Johns Hopkins Asthma & Allergy Center, 5501 Hopkins Bayview Circle, Room 3B.71, Baltimore, MD 21224, USA. Email: [email protected]. Abstract: Allergic asthma has a global prevalence, morbidity, and mortality. Many environmental factors, such as pollutants and allergens, are highly relevant to allergic asthma. The most important pathological symptom of allergic asthma is airway inflammation. Accordingly, the unique role of reactive oxygen species (ROS) had been identified as a main reason for this respiratory inflammation. Many studies have shown that inhalation of different allergens can promote ROS generation. Recent studies have demonstrated that several pro-inflammatory mediators are responsible for the development of allergic asthma. Among these mediators, endogenous or exogenous ROS are responsible for the airway inflammation of allergic asthma. Furthermore, several inflammatory cells induce ROS and allergic asthma development.
  • Metabolic Enzyme Expression Highlights a Key Role for MTHFD2 and the Mitochondrial Folate Pathway in Cancer

    Metabolic Enzyme Expression Highlights a Key Role for MTHFD2 and the Mitochondrial Folate Pathway in Cancer

    ARTICLE Received 1 Nov 2013 | Accepted 17 Dec 2013 | Published 23 Jan 2014 DOI: 10.1038/ncomms4128 Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer Roland Nilsson1,2,*, Mohit Jain3,4,5,6,*,w, Nikhil Madhusudhan3,4,5, Nina Gustafsson Sheppard1,2, Laura Strittmatter3,4,5, Caroline Kampf7, Jenny Huang8, Anna Asplund7 & Vamsi K. Mootha3,4,5 Metabolic remodeling is now widely regarded as a hallmark of cancer, but it is not clear whether individual metabolic strategies are frequently exploited by many tumours. Here we compare messenger RNA profiles of 1,454 metabolic enzymes across 1,981 tumours spanning 19 cancer types to identify enzymes that are consistently differentially expressed. Our meta- analysis recovers established targets of some of the most widely used chemotherapeutics, including dihydrofolate reductase, thymidylate synthase and ribonucleotide reductase, while also spotlighting new enzymes, such as the mitochondrial proline biosynthetic enzyme PYCR1. The highest scoring pathway is mitochondrial one-carbon metabolism and is centred on MTHFD2. MTHFD2 RNA and protein are markedly elevated in many cancers and correlated with poor survival in breast cancer. MTHFD2 is expressed in the developing embryo, but is absent in most healthy adult tissues, even those that are proliferating. Our study highlights the importance of mitochondrial compartmentalization of one-carbon metabolism in cancer and raises important therapeutic hypotheses. 1 Unit of Computational Medicine, Department of Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. 2 Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. 3 Broad Institute, Cambridge, Massachusetts 02142, USA. 4 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression

    1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression

    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
  • Flavonoid Rutin Increases Thyroid Iodide Uptake in Rats

    Flavonoid Rutin Increases Thyroid Iodide Uptake in Rats

    Flavonoid Rutin Increases Thyroid Iodide Uptake in Rats Carlos Frederico Lima Gonçalves, Maria Carolina de Souza dos Santos, Maria Gloria Ginabreda, Rodrigo Soares Fortunato, Denise Pires de Carvalho, Andrea Claudia Freitas Ferreira* Laboratório de Fisiologia Endócrina Doris Rosenthal, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil Abstract Thyroid iodide uptake through the sodium-iodide symporter (NIS) is not only an essential step for thyroid hormones biosynthesis, but also fundamental for the diagnosis and treatment of different thyroid diseases. However, part of patients with thyroid cancer is refractory to radioiodine therapy, due to reduced ability to uptake iodide, which greatly reduces the chances of survival. Therefore, compounds able to increase thyroid iodide uptake are of great interest. It has been shown that some flavonoids are able to increase iodide uptake and NIS expression in vitro, however, data in vivo are lacking. Flavonoids are polyhydroxyphenolic compounds, found in vegetables present in human diet, and have been shown not only to modulate NIS, but also thyroperoxidase (TPO), the key enzyme in thyroid hormones biosynthesis, besides having antiproliferative effect in thyroid cancer cell lines. Therefore, we aimed to evaluate the effect of some flavonoids on thyroid iodide uptake in Wistar rats in vivo. Among the flavonoids tested, rutin was the only one able to increase thyroid iodide uptake, so we decided to evaluate the effect of this flavonoid on some aspects of thyroid hormones synthesis and metabolism. Rutin led to a slight reduction of serum T4 and T3 without changes in serum thyrotropin (TSH), and significantly increased hypothalamic, pituitary and brown adipose tissue type 2 deiodinase and decreased liver type 1 deiodinase activities.